Scholars Central

Conference abstract

SNAP NAPPA Microarrays and mass spectrometry for personalized medicine and molecular diagnosis

Authors: Evgeniya Peshkova, Claudio Nicolini

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Towards a new generation of Personalized Medicine an innovative self-assembling protein microarray, based on NAPPA and SNAP tag coupled to E. coli cell free expression system, is here introduced along with Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF). This aims indeed to develop in clininical setting a standardized procedure to identify the leading protein-protein interaction in a given pathology towards the enhancement of both diagnosis and therapy. In the process we employ ?Protein synthesis Using Recombinant Elements? (PURE) system which due to its high complexity has required ad hoc bioinformatic tools. The PURE system represents a step towards a totally defined in vitro transcription/ translation system, thus avoiding the ?black box? nature of the cell extract. The immediate advantage is the E. coli IVTT that respect to the RRL or human lysate proved an advantage for the MS analysis of the results. The presence of ?background? molecules, in fact, represents the main obstacle to the MS data interpretation. For this latter reason SpADS: An R Script for Mass Spectrometry Data Preprocessing before Data Mining an ad hoc script was implemented. SpADS provides useful preprocessing functions such binning, peak extractions, spectra background subtraction and dataset managing. Moreover, in its final version, it is able to perform peak recognition and amplitude independent subtraction functions were implemented. The MS samples are obtained from SNAP-NAPPA spots printed on gold coated glass slides in higher density, in order to obtain an amount of protein appropriate for MS analysis. The spots of 300 microns were printed in 12 boxes, each box with 100 identical spots. The sample genes immobilized as test cases were p53_Human (Cellular tumor antigen p53); CDK2_Human (Cyclin-dependent kinase), 2;Src_Human-SH2 (the SH2 domain of Proto-oncogene tyrosine-protein kinase),, PTPN11 (Human-SH2, the SH2 domain of Tyrosine-protein phosphatase non-receptor type 11). This represents a proof of principles with optimization in progress.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacogenomics & Pharmacoproteomics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Evgeniya Peshkova”
  • BylineArticles whose byline prints “Claudio Nicolini”